Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
Aimery de Gramont(Institut Hospitalier Franco Britannique), Andrea Bonetti(Italian Oncology Group of Clinical Research), N Le Bail, D. Papamichael(Centre Hospitalier René-Dubos), Abdel Hmissi(Centre Hospitalier René-Dubos), M. Homerin(Centre Hospitalier René-Dubos), Daniel Hendler(Centre Hospitalier René-Dubos), C. Boni(Ospedale Santa Maria), Jim Cassidy(University of Glasgow), Michel Seymour(University of Leeds), F. Morvan(École Nationale Supérieure de Chimie de Montpellier), Gilles Freyer(Centre Hospitalier René-Dubos), Andrés Cervantes(INCLIVA Health Research Institute), Arié Figer(Ontario Institute for Cancer Research), C. Wilson(Centre Hospitalier René-Dubos), Christophe Louvet(Institute Mutualiste Montsouris), H. Cortés-Funes(Centre Hospitalier René-Dubos), Filippo de Braud(University of Milan)
Cited by 3,818
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k